ArticleRisk management and healthcare policy2022
Clinical Risk Factors for Thoracic Ossification of the Ligamentum Flavum: A Cross-Sectional Study Based on Spinal Thoracic Three-Dimensional Computerized Tomography.
Article in Risk management and healthcare policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Prevalence and Radiological Features of Thoracic Ossification of the Ligamentum Flavum in Korea-A Retrospective Comparative Cohort Study Using MRI.Journal of clinical medicine · 2026Article
- Potential Influence of Sagittal Parameters in the Pathogenesis of Patients With the Thoracic Ossification of the Ligamentum Flavum.Orthopaedic surgery · 2025Article
- Laminoplasty and In-Site Regrafting for the Treatment of Thoracic Ossification of the Ligamentum Flavum: A Surgical Technique.Orthopaedic surgery · 2025Article
- The involvement of epidural fat in ossification of the ligamentum flavum: From the perspective of exosomal proteome.Heliyon · 2024Article
- Degenerative Thoracic Myelopathy: A Scoping Review of Epidemiology, Genetics, and Pathogenesis.Global spine journal · 2024Article
- The Quality of Life of the Patients with Thoracic Ossification of the Ligamentum Flavum after Surgery Using EQ-5D-5L.Orthopaedic surgery · 2024Article
- Pathogenesis of thoracic ossification of the ligamentum flavum.Frontiers in pharmacology · 2024Review
- Surgical outcomes of percutaneous endoscopic thoracic decompression in the treatment of multi-segment thoracic ossification of the ligamentum flavum.Acta neurochirurgica · 2023Article
- Three-dimensional imaging analysis for the diagnosis of dural ossification in thoracic ossification of the ligamentum flavum: a multicenter study.Quantitative imaging in medicine and surgery · 2023Article
- High Systemic Immune-Inflammation Index and Body Mass Index Are Independent Risk Factors of the Thoracic Ossification of the Ligamentum Flavum.Mediators of inflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inconsistent results of the clinical risk factors associated with thoracic ossification of the ligamentum flavum (TOLF) have been reported in limited previous studies. Purpose: This retrospective study aimed to investigate the potential risk factors for TOLF by a retrospective cross-sectional study, which may provide valuable experience for further clinical and pathophysiological research. Methods: A total of 2247 asymptomatic participants, who underwent spinal thoracic three-dimensional computerized tomography (3D-CT) scans at our institution from January 2016 to December 2019, were enrolled in this study according to the screening criteria. Demographic information such as age, sex, height, weight, body mass index (BMI), smoking and drinking history, diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse pressure (PP) were recorded. Laboratory results included serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), uric acid (UA), creatinine (Cr), calcium, and phosphorus. Participants were divided into TOLF group and non-TOLF group in accordance with the thoracic 3D-CT manifestation. Results: TOLF was observed in 153 (6.81%) asymptomatic participants. Comparison of demographic data and laboratory examinations between the two groups showed that participants in the TOLF group were older, had a higher BMI, as well as higher levels of DBP. In addition, there was no significant difference in sex, drinking, tobacco use, SBP, TC, TG, PP, and levels of LDL-C, HDL-C, sUA, sCr, calcium, and phosphorus between the two groups. Furthermore, dichotomous logistic regression analyses revealed that age (OR = 1.018, p = 0.041) and BMI (OR = 1.090, p < 0.001) were risk factors for TOLF. Conclusion: Our study reveals that age and BMI are clinical risk factors for the development of TOLF, while age cannot be identified as an independent risk factor for female in subgroup analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.